239P Genomic landscape of metastatic ER+/HER2- breast cancer (BC) with loss of estrogen (ER) and/or progesterone (PR) receptor von Migliaccio, I., Paoli, M., Guarducci, C., Galardi, F., Biagioni, C., Biganzoli, L., Benelli, M., Malorni, L.

Volltext

Abstract PD7-12: Inhibition of CDK7 overcomes resistance to CDK4/6 inhibitors in hormone receptor positive breast cancer cells von Guarducci, C, Nardone, A, Feiglin, A, Migliaccio, I, Malorni, L, Bonechi, M, Benelli, M, Di Leo, A, Hodgson, G, Shapiro, G, Brown, M, Jeselsohn, R

Volltext

Metabolomic analysis as a tool to identify breast cancer (BC) cell lines resistant to palbociclib (PD) von Bonechi, M., Guarducci, C., Meoni, G., Tenori, L., Biagioni, C., Schiff, R., Osborne, C.K., Luchinat, C., Malorni, L., Migliaccio, I.

Volltext

Gene signatures as potential predictive markers of response to neoadjuvant chemotherapy in ER+/HER2+ breast cancer patients von Risi, E., Grilli, A., Migliaccio, I., Biagioni, C., Guarducci, C., Bonechi, M., McCartney, A., Vitale, S., Biganzoli, L., Bicciato, S., Di Leo, A., Malorni, L.

Volltext

Abstract P6-02-07: Metabolomic analysis by nuclear magnetic resonance spectroscopy discriminates hormone receptor positive/HER2 negative breast cancer cell lines resistant to palbo... von Bonechi, M, Guarducci, C, Meoni, G, Tenori, L, Biagioni, C, Schiff, R, Osborne, CK, Luchinat, C, Di Leo, A, Malorni, L, Migliaccio, I

Volltext

Abstract P1-09-13: A RB-1 loss-of-function gene-signature (RBsig) predicts resistance to neoadjuvant chemotherapy in HER2+/ER+ breast cancer patients von Risi, E, Grilli, A, Migliaccio, I, Biagioni, C, Guarducci, C, Bonechi, M, Hart, CD, Biganzoli, L, Bicciato, S, Di Leo, A, Malorni, L

Volltext

45P Integrated multi-omic analysis of HR+/HER2- breast cancer cell lines resistant to CDK4/6 inhibitors von Guarducci, C., Romagnoli, D., Nardone, A., Biagioni, C., Bonechi, M., Capaccioli, G., Galardi, F., Santaniello, F., Biganzoli, L., Cescon, D.W., Schiff, R., Lupien, M., Benelli, M., Migliaccio, I., Malorni, L.

Volltext

Abstract P6-09-02: Effects of palbociclib on thymidine kinase-1 (TK1) in hormone receptor positive (HR+) breast cancer cell lines von Bonechi, M, Migliaccio, I, Benelli, M, Romagnoli, D, Bergqvist, M, Mattsson, K, Boccalini, G, Capaccioli, G, De Luca, F, Galardi, F, Biagioni, C, Risi, E, McCartney, A, Rossi, L, Osborne, CK, Schiff, R, De Angelis, C, Guarducci, C, Di Leo, A, Malorni, L

Volltext

13IN - Introduction: Luminal A and B: How Curable are they? von Di Leo, A., Turner, N.H., Malorni, L., Guarducci, C.

Volltext

Introduction: Luminal A and B: How Curable are they? von Di Leo, A., Turner, N.H., Malorni, L., Guarducci, C.

Volltext

AP-2gamma as a novel biomarker of endocrine resistance: Results from the TransCONFIRM study von Malorni, L., Biagioni, C., Guarducci, C., Bonechi, M., Capaccioli, G., Jeselsohn, R., Barry, W.T., Laing, N., Di Leo, A., Migliaccio, I.

Volltext

Low hormone receptor (HR) status and the benefit of hormonal therapy (HT) in patients with early breast cancer (EBC) von Guarducci, C., Bonechi, M., Biagioni, C., Malorni, L., Biganzoli, L., Truglia, M.C., Vitale, S., Soldi, G., Di Leo, A., Migliaccio, I.

Volltext

Identification of gene expression signatures of palbociclib (PD) response in breast cancer (BC) von Migliaccio, I., Piazza, S., Verardo, R., Guarducci, C., Bonechi, M., Ciani, Y., Moretti, E., Siclari, O., Di Leo, A., Malorni, L.

Volltext

Efficacy of Fulvestrant According to Duration and Type of Adjuvant Endocrine Treatment, in Metastatic Breast Cancer Patients Enrolled in the Confirm Trial von Malorni, L., Biagioni, C., Thirlwell, J., Guarducci, C., Bonechi, M., Rukazenkov, Y., Jerusalem, G., Martin, M., di Leo, A., Migliaccio, I.

Volltext

31PEFFICACY OF FULVESTRANT ACCORDING TO DURATION AND TYPE OF ADJUVANT ENDOCRINE TREATMENT, IN METASTATIC BREAST CANCER PATIENTS ENROLLED IN THE CONFIRM TRIAL von Malorni, L., Biagioni, C., Thirlwell, J., Guarducci, C., Bonechi, M., Rukazenkov, Y., Jerusalem, G., Martin, M., di Leo, A., Migliaccio, I.

Volltext

Prognostic Role of Luminal Subtype in Metastatic Breast Cancer Patients Treated with Fulvestrant in the Confirm Trial von Migliaccio, I., Biagioni, C., Thirlwell, J., Galardi, F., Guarducci, C., Capaccioli, G., Truglia, M., Rukazenkov, Y., di Leo, A., Malorni, L.

Volltext

30PPROGNOSTIC ROLE OF LUMINAL SUBTYPE IN METASTATIC BREAST CANCER PATIENTS TREATED WITH FULVESTRANT IN THE CONFIRM TRIAL von Migliaccio, I., Biagioni, C., Thirlwell, J., Galardi, F., Guarducci, C., Capaccioli, G., Truglia, M., Rukazenkov, Y., di Leo, A., Malorni, L.

Volltext

Abstract OT2-6-01: Phase 2 study of palbociclib (CDK 4/6 inhibitor) for ER positive, HER2- negative post-menopausal advanced breast cancer patients recurring after hormonal therapy... von Malorni, L, Sanna, G, Pestrin, M, Siclari, O, Biganzoli, L, Biagioni, C, Cappadona, S, Migliaccio, I, Guarducci, C, Boni, L, Baldari, D, Minisini, AM, Curigliano, G, Koehler, M, Buyse, M, Di Leo, A

Volltext

Assessing Health Gains: A Cost-Utility Analysis von Guarducci, G, Siragusa, C, Gurnari, J, Gentile, A M, Nante, N

Volltext

How to reduce erroneous Emergency Department admissions for the frail elderly von Guarducci, G, Lorenzini, C, Ciacci, D, Righi, L, Pastorelli, M, Nante, N

Volltext